These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28221219)

  • 21. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
    Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk calculators and updated tools to select and plan a repeat biopsy for prostate cancer detection.
    Sorokin I; Mian BM
    Asian J Androl; 2015; 17(6):864-9. PubMed ID: 26112489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
    Ulmert D; O'Brien MF; Bjartell AS; Lilja H
    Nat Rev Urol; 2009 Jul; 6(7):384-91. PubMed ID: 19578355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
    van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
    Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
    Morote J; Celma A; Roche S; de Torres IM; Mast R; Semedey ME; Regis L; Planas J
    Eur Urol Oncol; 2019 Nov; 2(6):664-669. PubMed ID: 31411977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
    Hendriks RJ; van der Leest MMG; Dijkstra S; Barentsz JO; Van Criekinge W; Hulsbergen-van de Kaa CA; Schalken JA; Mulders PFA; van Oort IM
    Prostate; 2017 Oct; 77(14):1401-1407. PubMed ID: 28853167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
    Vickers A; Vertosick EA; Sjoberg DD; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
    J Urol; 2018 Jun; 199(6):1470-1474. PubMed ID: 29366640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
    Heijnsdijk EA; Denham D; de Koning HJ
    Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [PSA and blood test diagnostics of prostate cancer].
    Seikkula H; Pettersson K; Boström PJ
    Duodecim; 2015; 131(17):1547-52. PubMed ID: 26548101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate Volume Index Is Able to Differentiate between Prostatic Chronic Inflammation and Prostate Cancer in Patients with Normal Digital Rectal Examination and Prostate-Specific Antigen Values <10 ng/mL: Results of 564 Biopsy Naïve Cases.
    Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Panunzio A; De Michele M; Brunelli M; Cerruto MA; Migliorini F; Siracusano S; Artibani W
    Urol Int; 2019; 103(4):415-422. PubMed ID: 31466070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.
    Maccini MA; Westfall NJ; Van Bokhoven A; Lucia MS; Poage W; Maroni PD; Wilson SS; Glodé LM; Arangua P; Newmark J; Steiner M; Werahera PN; Crawford ED
    Prostate; 2018 May; 78(7):506-511. PubMed ID: 29460452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
    Vickers A; Cronin A; Roobol M; Savage C; Peltola M; Pettersson K; Scardino PT; Schröder F; Lilja H
    J Clin Oncol; 2010 May; 28(15):2493-8. PubMed ID: 20421547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
    Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
    Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
    Vickers AJ; Till C; Tangen CM; Lilja H; Thompson IM
    J Natl Cancer Inst; 2011 Mar; 103(6):462-9. PubMed ID: 21350221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of the Prostate Health Index and Density in 3 Outpatient Centers to Avoid Unnecessary Prostate Biopsies.
    Schulze A; Christoph F; Sachs M; Schroeder J; Stephan C; Schostak M; Koenig F
    Urol Int; 2020; 104(3-4):181-186. PubMed ID: 32224611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining prostate cancer risk before prostate biopsy.
    Pal RP; Maitra NU; Mellon JK; Khan MA
    Urol Oncol; 2013 Nov; 31(8):1408-18. PubMed ID: 22795499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnostic significance of multiparametric MRI combined with US-fusion guided biopsy of the prostate in patients with increased PSA levels and negative standard biopsy results to detect significant prostate cancer - Correlation with the Gleason score. Korrelation mit dem Gleason Score].
    Hoffmann MA; Wieler HJ; Jakobs FM; Taymoorian K; Gerhards A; Miederer M; Schreckenberger M
    Nuklearmedizin; 2017 Aug; 56(4):147-155. PubMed ID: 28715042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
    Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
    BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.